The signal transduction mediated by erythropoietin and proinflammatory cytokines in the JAK/STAT pathway in the children with cerebral palsy

Brain and Development

Volumn 31, Issue 3, 2009, Pages 200-207

  Tao, Weiyuan ^a   Wen, Fang ^a   Zhang, Hong ^a   Liu, Guheng ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Cerebral palsy; Erythropoietin; Inflammatory cytokines; JAK STAT pathway; Neuro endocrine immune network; Neurodevelopmental treatment

Indexed keywords

CYTOKINE RECEPTOR; ERYTHROPOIETIN; HYPOXIA INDUCIBLE FACTOR 1; INTERLEUKIN 6; JANUS KINASE; PROTEIN INHIBITOR OF ACTIVATED STAT; STAT PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; TUMOR NECROSIS FACTOR ALPHA;

ACUTE STRESS; CEREBRAL PALSY; CYTOKINE RELEASE; HUMAN; MEDIATOR RELEASE; NEGATIVE FEEDBACK; NEUROPROTECTION; PROTEIN FAMILY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CEREBRAL PALSY; CYTOKINES; ERYTHROPOIESIS; ERYTHROPOIETIN; FEEDBACK, BIOCHEMICAL; HUMANS; JANUS KINASES; MICE; NEUROPROTECTIVE AGENTS; PROTEIN INHIBITORS OF ACTIVATED STAT; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; RECEPTORS, CYTOKINE; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 59149088251     PISSN: 03877604     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.braindev.2008.06.011     Document Type: Review

References (65)

1. Mutch L., Alberman E., Hagberg B., Kodama K., and Perat M.V. Cerebral palsy epidemiology: where are we now and where are we going?. Dev Med Child Neurol 34 (1992) 547-551
2. Koman L.A., Smith B.P., and Shilt J.S. Cerebral palsy. Lancet 363 (2004) 1619-1631
3. Farrell F., and Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 9 (2004) 18-30
4. Sasaki R. Pleiotropic functions of erythropoietin. Intern Med 42 (2003) 142-149
5. Genc S., Koroglu T., and Genc K. Review: erythropoietin and the nervous system. Brain Res 1000 (2004) 19-31
6. Lappin T. The cellular biology of erythropoietin receptors. Oncologist 8 (2003) 15-18
7. Spandou E., Papoutsopoulou S., Soubasi V., Karkavelas G., Simeonidou C., Kremenopoulos G., et al. Hypoxia-ischemia affects erythropoietin and erythropoietin receptor expression pattern in the neonatal rat brain. Brain Res 1021 (2004) 167-172
8. Jacobsson B. Infectious and inflammatory mechanisms in preterm birth and cerebral palsy. Eur J Obstet Gynecol Reprod Biol 115 (2004) 159-160
9. Kadhim H., and Sebire G. Immune mechanisms in the pathogenesis of cerebral palsy: implication of proinflammatory cytokines and T lymphocytes. Eur J Paediatr Neurol 6 (2002) 139-142
10. Sun Y., Wen F., Yao H.Y., Xiao L., Chen Z.L., and Wang J.C. Role of proinflammatory cytokines in the pathogenesis of cerebral palsy (in China). Stroke Nerv Dis 12 (2005) 359-361
11. Yao H.Y., Wen F., Sun Y., Xiao L., Chen Z.L., and Wang J.C. The effect of NDT on erythropoietin levels in cerebral palsy (in China). Stroke Nerv Dis 12 (2005) 356-358
12. Brines M.L., Ghezzi P., Keenan S., Agnello D., de Lanerolle N.C., Cerami C., et al. From the Cover: erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 97 (2000) 10526-10531
13. Siren A.L., Fratelli M., Brines M., Goemans C., Casagrande S., Lewczuk P., et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 98 (2001) 4044-4049
14. Agnello D., Bigini P., Villa P., Mennini T., Cerami A., Brines M.L., et al. Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res 952 (2002) 128-134
15. Semenza G.L., and Wang G.L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12 (1992) 5447-5454
16. Marti H.H., Bernaudin M., Petit E., and Bauer C. Neuroprotection and angiogenesis: dual role of erythropoietin in brain Ischemia. News Physiol Sci 15 (2000) 225-229
17. Villa P., Bigini P., Mennini T., Agnello D., Laragione T., Cagnotto A., et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 198 (2003) 971-975
18. Beleslin-Cokic B.B., Cokic V.P., Yu X., Weksler B.B., Schechter A.N., and Noguchi C.T. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood 104 (2004) 2073-2080
19. Kawakami M., Iwasaki S., Sato K., and Takahashi M. Erythropoietin inhibits calcium-induced neurotransmitter release from clonal neuronal cells. Biochem Biophys Res Commun 279 (2000) 293-297
20. Koshimura K., Murakami Y., Sohmiya M., Tanaka J., and Kato Y. Effects of erythropoietin on neuronal activity. J Neurochem 72 (1999) 2565-2572
21. Tabira T., Konishi Y., and Gallyas Jr. F. Neurotrophic effect of hematopoietic cytokines on cholinergic and other neurons in vitro. Int J Dev Neurosci 13 (1995) 241-252
22. Martinez-Estrada O.M., Rodriguez-Millan E., Gonzalez-De Vicente E., Reina M., Vilaro S., and Fabre M. Erythropoietin protects the in vitro blood-brain barrier against VEGF-induced permeability. Eur J Neurosci 18 (2003) 2538-2544
23. Li W., Maeda Y., Yuan R.R., Elkabes S., Cook S., and Dowling P. Beneficial effect of erythropoietin on experimental allergic encephalomyelitis. Ann Neurol 56 (2004) 767-777
24. Murthy V., and Kennea N.L. Antenatal infection/inflammation and fetal tissue injury. Best Pract Res Clin Obstet Gynaecol 21 (2007) 479-489
25. Leviton A., and Dammann O. Coagulation, inflammation, and the risk of neonatal white matter damage. Pediatr Res 55 (2004) 541-545
26. Phares T.W., Kean R.B., Mikheeva T., and Hooper D.C. Regional differences in blood-brain barrier permeability changes and inflammation in the apathogenic clearance of virus from the central nervous system. J Immunol 176 (2006) 7666-7675
27. Lu Q.Y., and Wang Q.G. The etiological research of cerebral palsy (in China). Chin J Rehabil Theory Pract 9 (2003) 191-192
28. Shalak L.F., Laptook A.R., Jafri H.S., Ramilo O., and Perlman J.M. Clinical chorioamnionitis, elevated cytokines, and brain injury in term infants. Pediatrics 110 (2002) 673-680
29. Winkelmann J.C., Penny L.A., Deaven L.L., Forget B.G., and Jenkins R.B. The gene for the human erythropoietin receptor: analysis of the coding sequence and assignment to chromosome 19p. Blood 76 (1990) 24-30
30. Mulcahy L. The erythropoietin receptor. Semin Oncol 28 (2001) 19-23
31. Yamaoka K., Saharinen P., Pesu M., Holt III V.E., Silvennoinen O., and O'Shea J.J. The Janus kinases (Jaks). Genome Biol 5 (2004) 253
32. Khwaja A. The role of Janus kinases in haemopoiesis and haematological malignancy. Br J Haematol 134 (2006) 366-384
33. Musso T., Johnston J.A., Linnekin D., Varesio L., Rowe T.K., O'Shea J.J., et al. Regulation of JAK3 expression in human monocytes: phosphorylation in response to interleukins 2, 4, and 7. J Exp Med 181 (1995) 1425-1431
34. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
35. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J.P., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia And myeloid metaplasia with myelofibrosis. Cancer Cell 7 (2005) 387-397
36. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352 (2005) 1779-1790
37. Zhang F., Wang S., Cao G., Gao Y., and Chen J. Signal transducers and activators of transcription 5 contributes to erythropoietin-mediated neuroprotection against hippocampal neuronal death after transient global cerebral ischemia. Neurobiol Dis 25 (2007) 45-53
38. Shuai K., Stark G.R., Kerr I.M., and Darnell Jr. J.E. A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma. Science 261 (1993) 1744-1746
39. Carpenter L.R., Yancopoulos G.D., and Stahl N. General mechanisms of cytokine receptor signaling. Adv Protein Chem 52 (1998) 109-140
40. Vinkemeier U., Cohen S.L., Moarefi I., Chait B.T., Kuriyan J., and Darnell Jr. J.E. DNA binding of in vitro activated Stat1 alpha, Stat1 beta and truncated Stat1: interaction between NH2-terminal domains stabilizes binding of two dimers to tandem DNA sites. EMBO J 15 (1996) 5616-5626
41. Zhong Z., Wen Z., and Darnell Jr. J.E. Stat3 and Stat4: members of the family of signal transducers and activators of transcription. Proc Natl Acad Sci USA 91 (1994) 4806-4810
42. Tonstad S., Sundt E., Ose L., Hagve T.A., Fruchart J.C., Bard J.M., et al. The effect of growth hormone on low-density lipoprotein cholesterol and lipoprotein (a) levels in familial hypercholesterolemia. Metabolism 45 (1996) 1415-1421
43. Gorlich D., and Mattaj I.W. Nucleocytoplasmic transport. Science 271 (1996) 1513-1518
44. Koepp D.M., and Silver P.A. A GTPase controlling nuclear trafficking: running the right way or walking randomly?. Cell 87 (1996) 1-4
45. Pollard V.W., Michael W.M., Nakielny S., Siomi M.C., Wang F., and Dreyfuss G. A novel receptor-mediated nuclear protein import pathway. Curr Biol 10 (2000) 687-696
46. Ohno M., Fornerod M., and Mattaj I.W. Nucleocytoplasmic transport: the last 200 nanometers. Cell 92 (1998) 327-336
47. Livnah O., Stura E.A., Middleton S.A., Johnson D.L., Jolliffe L.K., and Wilson I.A. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science 283 (1999) 987-990
48. Penta K., and Sawyer S.T. Erythropoietin induces the tyrosine phosphorylation, nuclear translocation, and DNA binding of STAT1 and STAT5 in erythroid cells. J Biol Chem 270 (1995) 31282-31287
49. Goldsmith M.A., Mikami A., You Y., Liu K.D., Thomas L., Pharr P., et al. Absence of cytokine receptor-dependent specificity in red blood cell differentiation in vivo. Proc Natl Acad Sci USA 95 (1998) 7006-7011
50. Kirito K., Nakajima K., Watanabe T., Uchida M., Tanaka M., Ozawa K., et al. Identification of the human erythropoietin receptor region required for Stat1 and Stat3 activation. Blood 99 (2002) 102-110
51. Kretz A., Happold C.J., Marticke J.K., and Isenmann S. Erythropoietin promotes regeneration of adult CNS neurons via Jak2/Stat3 and PI3K/AKT pathway activation. Mol Cell Neurosci 29 (2005) 569-579
52. Yoshimura A., Nishinakamura H., Matsumura Y., and Hanada T. Negative regulation of cytokine signaling and immune responses by SOCS proteins. Arthritis Res Ther 7 (2005) 100-110
53. Nicholson S.E., De Souza D., Fabri L.J., Corbin J., Willson T.A., Zhang J.G., et al. Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc Natl Acad Sci USA 97 (2000) 6493-6498
54. Krebs D.L., and Hilton D.J. SOCS: physiological suppressors of cytokine signaling. J Cell Sci 113 (2000) 2813-2819
55. Stevenson N.J., Haan S., McClurg A.E., McGrattan M.J., Armstrong M.A., Heinrich P.C., et al. The chemoattractants, IL-8 and formyl-methionyl-leucyl-phenylalanine, regulate granulocyte colony-stimulating factor signaling by inducing suppressor of cytokine signaling-1 expression. J Immunol 173 (2004) 3243-3249
56. Tan J.C., and Rabkin R. Suppressors of cytokine signaling in health and disease. Pediatr Nephrol 20 (2005) 567-575
57. Schmidt D., and Muller S. Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity. Proc Natl Acad Sci USA 99 (2002) 2872-2877
58. Shuai K. Regulation of cytokine signaling pathways by PIAS proteins. Cell Res 16 (2006) 196-202
59. Kashiwada M., Giallourakis C.C., Pan P.Y., and Rothman P.B. Immunoreceptor tyrosine-based inhibitory motif of the IL-4 receptor associates with SH2-containing phosphatases and regulates IL-4-induced proliferation. J Immunol 167 (2001) 6382-6387
60. Klingmuller U., Lorenz U., Cantley L.C., Neel B.G., and Lodish H.F. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 80 (1995) 729-738
61. Uchida T., Matozaki T., Noguchi T., Yamao T., Horita K., Suzuki T., et al. Insulin stimulates the phosphorylation of Tyr538 and the catalytic activity of PTP1C, a protein tyrosine phosphatase with Src homology-2 domains. J Biol Chem 269 (1994) 12220-12228
62. Jiao H., Berrada K., Yang W., Tabrizi M., Platanias L.C., and Yi T. Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1. Mol Cell Biol 16 (1996) 6985-6992
63. Neel B.G., Gu H., and Pao L. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci 28 (2003) 284-293
64. Symes A., Stahl N., Reeves S.A., Farruggella T., Servidei T., Gearan T., et al. The protein tyrosine phosphatase SHP-2 negatively regulates ciliary neurotrophic factor induction of gene expression. Curr Biol 7 (1997) 697-700
65. Levy D.E., and Loomis C.A. STAT3 signaling and the hyper-IgE syndrome. N Engl J Med 357 (2007) 1655-1658